Tebentafusp is a pharmacological breakthrough in the fight against a deadly disease.
Belzutifan by Merck & Co. is for the treatment of renal cell carcinoma, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors.
Gefapixant will reduce cough frequency, thereby improving patients’ quality of life.
Roche offered a convenient replacement for the traditional Lucentis.
Scynexis offered ibrexafungerp, a new antifungal medication for vulvovaginal candidiasis treatment.
Daridorexant will help treat insomnia.
An oral antiviral drug by Merck & Co. has joined the armamentarium of the pharmacological fight against COVID-19.